Schlichter, Bogard & Denton Investigating TNF-blocker Lymphoma, Leukemia, and other Cancer Cases

FOR IMMEDIATE RELEASE
(Free-Press-Release.com) August 4, 2009 --

The FDA announced today, Tuesday, August 4, that a new black box warning will be added to TNF (tumor necrosis factor) blockers including Enbrel, Humira, Remicade, Cimzia, and Simponi. The warning will emphasis the risk of developing cancers such as lymphoma or leukemia when taking one of these drugs. TNF-blockers are used to treat autoimmune conditions such as psoriasis and rheumatoid arthritis. A black-box warning is the most serious warning that the FDA requires for prescription drugs. For more information, visit the FDA website: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm175843.htm

The attorneys at Schlichter, Bogard, and Denton are currently leading litigation involving plaintiffs who have suffered serious infections as a result of using a TNF-blocker. Schlichter, Bogard and Denton is now also investigating cases in which a TNF-blocker caused cancer, including leukemia or lymphoma.

If you or a loved one has been injured by a TNF blocker such as Enbrel, Humira, Remicade, Cimzia, and Simponi, contact the attorneys at Schlichter, Bogard and Denton at 314-621-6115 or bwilkins@uselaws.com for a free consultation. Further information available at http://www.druginjuryinformation.com/enbrel.html .